{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:47:34Z","timestamp":1794944854879,"version":"4.9.1"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Neutrophil extracellular traps are associated with a unique form of cell death distinct from apoptosis or necrosis, whereby invading microbes are trapped and killed. Neutrophil extracellular traps can contribute to autoimmunity by exposing autoantigens, inducing IFN-\u03b1 production, and activating the complement system. The association of neutrophil extracellular traps with autoimmune diseases, particularly systemic lupus erythematosus, will be reviewed. Increased neutrophil extracellular trap formation is seen in psoriasis, antineutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid antibody syndrome rheumatoid arthritis, and systemic lupus erythematosus. Neutrophil extracellular traps may promote thrombus formation in antineutrophil cytoplasmic antibody-associated vasculitis and antiphospholipid antibody syndrome. In systemic lupus erythematosus, increased neutrophil extracellular trap formation is associated with increased disease activity and renal disease, suggesting that neutrophil extracellular traps could be a disease activity marker. Neutrophil extracellular traps can damage and kill endothelial cells and promote inflammation in atherosclerotic plaques, which may contribute to accelerated atherosclerosis in systemic lupus erythematosus. As neutrophil extracellular traps induce IFN-\u03b1 production, measuring neutrophil extracellular traps may estimate IFN-\u03b1 levels and identify which systemic lupus erythematosus patients have elevated levels and may be more likely to respond to emerging anti-IFN-\u03b1 therapies. In addition to anti-IFN-\u03b1 therapies, other novel agents, such as N-acetyl-cysteine, DNase I, and peptidylarginine deiminase inhibitor 4, target neutrophil extracellular traps. Neutrophil extracellular traps offer insight into the pathogenesis of autoimmune diseases and provide promise in developing disease markers and novel therapeutic agents in systemic lupus erythematosus. Priority areas for basic research based on clinical research insights will be identified, specifically the potential role of neutrophil extracellular traps as a biomarker and therapeutic target in systemic lupus erythematosus.<\/jats:p>","DOI":"10.1189\/jlb.5bt0615-234r","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T01:25:11Z","timestamp":1449883511000},"page":"265-278","source":"Crossref","is-referenced-by-count":160,"title":["At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases"],"prefix":"10.1093","volume":"99","author":[{"given":"April","family":"Barnado","sequence":"first","affiliation":[{"name":"Department of Medicine, Vanderbilt University , Nashville, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J","family":"Crofford","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University , Nashville, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim C","family":"Oates","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina , Charleston, South Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,11]]},"reference":[{"key":"2023013012482225700_B1","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"2023013012482225700_B2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jlb.59.2.229","article-title":"Rapid killing of human neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied by changes different from typical apoptosis or necrosis","volume":"59","author":"Takei","year":"1996","journal-title":"J. Leukoc. Biol."},{"key":"2023013012482225700_B3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1189\/jlb.5BT0615-247R","article-title":"At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases","volume":"99","author":"Grayson","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"2023013012482225700_B4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"2023013012482225700_B5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.1959","article-title":"Netting neutrophils in autoimmune small-vessel vasculitis","volume":"15","author":"Kessenbrock","year":"2009","journal-title":"Nat. Med."},{"key":"2023013012482225700_B6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J. Immunol."},{"key":"2023013012482225700_B7","doi-asserted-by":"crossref","first-page":"178ra40","DOI":"10.1126\/scitranslmed.3005580","article-title":"NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis","volume":"5","author":"Khandpur","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2023013012482225700_B8","first-page":"66","article-title":"Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome","volume":"32","author":"Leffler","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"2023013012482225700_B9","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"2023013012482225700_B10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00281-013-0384-6","article-title":"Molecular mechanisms regulating NETosis in infection and disease","volume":"35","author":"Branzk","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"2023013012482225700_B11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000205281","article-title":"Mouse neutrophil extracellular traps in microbial infections","volume":"1","author":"Ermert","year":"2009","journal-title":"J. Innate Immun."},{"issue":"Suppl 1","key":"2023013012482225700_B12","doi-asserted-by":"crossref","DOI":"10.1186\/ar2884","article-title":"Potential role of IFN\u03b1 in adult lupus","volume":"12","author":"R\u00f6nnblom","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"2023013012482225700_B13","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012482225700_B14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1681\/ASN.2013060606","article-title":"Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis","volume":"25","author":"Nakazawa","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"2023013012482225700_B15","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.4049\/jimmunol.1102404","article-title":"Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease","volume":"188","author":"Leffler","year":"2012","journal-title":"J. Immunol."},{"key":"2023013012482225700_B16","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/ar4264","article-title":"Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus","volume":"15","author":"Leffler","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"2023013012482225700_B17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fimmu.2012.00333","article-title":"Abundant neutrophil extracellular traps in thrombus of patient with microscopic polyangiitis","volume":"3","author":"Nakazawa","year":"2012","journal-title":"Front. Immunol."},{"key":"2023013012482225700_B18","doi-asserted-by":"crossref","first-page":"R122","DOI":"10.1186\/ar4579","article-title":"Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility","volume":"16","author":"Sur Chowdhury","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"2023013012482225700_B19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J. Clin. Invest."},{"key":"2023013012482225700_B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9440(10)62951-3","article-title":"The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies","volume":"167","author":"Xiao","year":"2005","journal-title":"Am. J. Pathol."},{"key":"2023013012482225700_B21","doi-asserted-by":"crossref","first-page":"20736","DOI":"10.1073\/pnas.1109227109","article-title":"IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis","volume":"108","author":"Kelley","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012482225700_B22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.2053","article-title":"Extracellular histones are major mediators of death in sepsis","volume":"15","author":"Xu","year":"2009","journal-title":"Nat. Med."},{"key":"2023013012482225700_B23","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012482225700_B24","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/art.11454","article-title":"Thrombosis and pediatric Wegener\u2019s granulomatosis: acquired and genetic risk factors for hypercoagulability","volume":"49","author":"Von Scheven","year":"2003","journal-title":"Arthritis Rheum."},{"key":"2023013012482225700_B25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group.","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2023013012482225700_B26","doi-asserted-by":"crossref","first-page":"15541","DOI":"10.1074\/jbc.275.20.15541","article-title":"High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II","volume":"275","author":"Ma","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2023013012482225700_B27","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2011-03-344671","article-title":"A novel pathway for human endothelial cell activation by antiphospholipid\/anti-\u03b22 glycoprotein I antibodies","volume":"119","author":"Allen","year":"2012","journal-title":"Blood"},{"key":"2023013012482225700_B28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0038-1650265","article-title":"Anticardiolipin and anti-beta 2-GPI are two distinct populations of autoantibodies","volume":"75","author":"Sorice","year":"1996","journal-title":"Thromb. Haemost."},{"key":"2023013012482225700_B29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.rdc.2010.02.001","article-title":"Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation","volume":"36","author":"Deane","year":"2010","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"2023013012482225700_B30","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1186\/ar2523","article-title":"Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination","volume":"10","author":"Kidd","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"2023013012482225700_B31","doi-asserted-by":"crossref","first-page":"R458","DOI":"10.1186\/ar1697","article-title":"Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity","volume":"7","author":"Lundberg","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"2023013012482225700_B32","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.20100239","article-title":"PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps","volume":"207","author":"Li","year":"2010","journal-title":"J. Exp. Med."},{"key":"2023013012482225700_B33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J. Immunol."},{"key":"2023013012482225700_B34","doi-asserted-by":"crossref","first-page":"73ra19","DOI":"10.1126\/scitranslmed.3001180","article-title":"Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus","volume":"3","author":"Lande","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2023013012482225700_B35","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2169\/internalmedicine.53.2570","article-title":"Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus","volume":"53","author":"Zhang","year":"2014","journal-title":"Intern. Med."},{"key":"2023013012482225700_B36","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1136\/annrheumdis-2013-204837","article-title":"Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2","volume":"74","author":"Carmona-Rivera","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"2023013012482225700_B37","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/art.38703","article-title":"Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"2023013012482225700_B38","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum."},{"key":"2023013012482225700_B39","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/art.39153","article-title":"Neutrophil-related gene expression and low-density granulocytes associated with disease activity and response to treatment in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"67","author":"Grayson","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"2023013012482225700_B40","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.4049\/jimmunol.0902199","article-title":"A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs","volume":"184","author":"Denny","year":"2010","journal-title":"J. Immunol."},{"issue":"Suppl 1","key":"2023013012482225700_B41","doi-asserted-by":"crossref","DOI":"10.1186\/ar2887","article-title":"Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN\u03b1 antibody, in systemic lupus erythematosus","volume":"12","author":"Yao","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"2023013012482225700_B42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am. J. Epidemiol."},{"key":"2023013012482225700_B43","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa035611","article-title":"Premature coronary-artery atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Asanuma","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2023013012482225700_B44","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheum."},{"key":"2023013012482225700_B45","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/blood-2003-09-3198","article-title":"Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity","volume":"103","author":"Rajagopalan","year":"2004","journal-title":"Blood"},{"key":"2023013012482225700_B46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.aaa8064","article-title":"Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis","volume":"349","author":"Warnatsch","year":"2015","journal-title":"Science"},{"key":"2023013012482225700_B47","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.niox.2010.01.001","article-title":"Nitric oxide donors release extracellular traps from human neutrophils by augmenting free radical generation","volume":"22","author":"Patel","year":"2010","journal-title":"Nitric Oxide"},{"key":"2023013012482225700_B48","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/art.37893","article-title":"Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus","volume":"65","author":"Garcia","year":"2013","journal-title":"Arthritis Rheum."},{"key":"2023013012482225700_B49","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/art.34502","article-title":"N-Acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Lai","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2023013012482225700_B50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2249.1996.d01-839.x","article-title":"The treatment of systemic lupus erythematosus (SLE) in NZB\/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone","volume":"106","author":"Macanovic","year":"1996","journal-title":"Clin. Exp. Immunol."},{"key":"2023013012482225700_B51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1191\/096120398678920037","article-title":"DNAse treatment does not improve the survival of lupus prone (NZB x NZW)F1 mice","volume":"7","author":"Verthelyi","year":"1998","journal-title":"Lupus"},{"key":"2023013012482225700_B52","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.4049\/jimmunol.1000224","article-title":"Antigen is required for maturation and activation of pathogenic anti-DNA antibodies and systemic inflammation","volume":"186","author":"Venkatesh","year":"2011","journal-title":"J. Immunol."},{"key":"2023013012482225700_B53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1191\/096120399678847380","article-title":"Recombinant human Dnase I (rhDNase) in patients with lupus nephritis","volume":"8","author":"Davis","year":"1999","journal-title":"Lupus"},{"key":"2023013012482225700_B54","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1172\/JCI67390","article-title":"Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus","volume":"123","author":"Knight","year":"2013","journal-title":"J. Clin. Invest."},{"key":"2023013012482225700_B55","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1136\/annrheumdis-2014-205365","article-title":"Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL\/lpr mice","volume":"74","author":"Knight","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"2023013012482225700_B56","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1182\/blood.V122.21.1235.1235","article-title":"Neutrophil extracelluar trap formation in PNH patients with and without a history of thrombosis\u2014effects of eculizumab","volume":"122","author":"Zeerleder","year":"2013","journal-title":"Blood"},{"key":"2023013012482225700_B57","volume-title":"2001 Innovative Therapies in Autoimmune Diseases","author":"Furie","year":"2001"},{"key":"2023013012482225700_B58","first-page":"22","article-title":"Effects of 1,25(OH)2D3 in immune response regulation of systemic lupus erithematosus (SLE) patient with hypovitamin D","volume":"7","author":"Wahono","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"Suppl 1","key":"2023013012482225700_B59","article-title":"Role of vitamin D in endothelial function and endothelial repair in clinically stable systemic lupus erythematosus","volume":"385","author":"Reynolds","year":"2015","journal-title":"Lancet"},{"key":"2023013012482225700_B60","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"2023013012482225700_B61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum."},{"key":"2023013012482225700_B62","volume-title":"2014 American College of Rheumatology and Association of Reproductive Health Professionals Annual Meeting","author":"Khamashta, M. Merrill","year":"2014"},{"key":"2023013012482225700_B63","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","article-title":"Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study","volume":"64","author":"McBride","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"Suppl 10","key":"2023013012482225700_B64","article-title":"Efficacy and safety of rontalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled phase 2 study","volume":"64","author":"Kalunian","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2023013012482225700_B65","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.4049\/jimmunol.0803600","article-title":"Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1\/Rab4-regulated lysosomal degradation","volume":"182","author":"Fernandez","year":"2009","journal-title":"J. Immunol."},{"key":"2023013012482225700_B66","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nrrheum.2011.153","article-title":"Structural modification of DNA\u2014a therapeutic option in SLE?","volume":"7","author":"Frese","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"2023013012482225700_B67","doi-asserted-by":"crossref","first-page":"e22043","DOI":"10.1371\/journal.pone.0022043","article-title":"PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection","volume":"6","author":"Hemmers","year":"2011","journal-title":"PLoS One"},{"key":"2023013012482225700_B68","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature09102","article-title":"TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus","volume":"465","author":"Guiducci","year":"2010","journal-title":"Nature"},{"key":"2023013012482225700_B69","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/rheumatology\/ket403","article-title":"Type I interferon blockade in systemic lupus erythematosus: where do we stand?","volume":"53","author":"Lauwerys","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2023013012482225700_B70","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-015-0394-x","article-title":"Targeting interferons in systemic lupus erythematosus: current and future prospects","volume":"75","author":"Mathian","year":"2015","journal-title":"Drugs"},{"key":"2023013012482225700_B71","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-alpha\/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2023013012482225700_B72","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2023013012482225700_B73","volume-title":"ClinicalTrials.gov","author":"State University of New York\u2014Upstate Medical University.","year":"2008"},{"key":"2023013012482225700_B74","volume-title":"ClinicalTrials.gov","author":"Novo Nordisk A\/S.","year":"2009"}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1189%2Fjlb.5BT0615-234R","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/99\/2\/265\/48175153\/jlb0265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/99\/2\/265\/48175153\/jlb0265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T13:36:40Z","timestamp":1677505000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/99\/2\/265\/6935919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,11]]},"references-count":74,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,12,11]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1189\/jlb.5bt0615-234r","relation":{},"ISSN":["0741-5400","1938-3673"],"issn-type":[{"value":"0741-5400","type":"print"},{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,2]]},"published":{"date-parts":[[2015,12,11]]}}}